Jon Foss-Skiftesvik1,2, Ulrik Kristoffer Stoltze3,4. 1. Department of Neurosurgery, Rigshospitalet University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark. jon.foss-skiftesvik@regionh.dk. 2. The Pediatric Oncology Research Laboratory, Department of Pediatrics and Adolescent Medicine, Rigshospitalet University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark. jon.foss-skiftesvik@regionh.dk. 3. The Pediatric Oncology Research Laboratory, Department of Pediatrics and Adolescent Medicine, Rigshospitalet University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark. 4. Department of Clinical Genetics, Rigshospitalet University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.
Abstract
BACKGROUND: Historically, few pediatric central nervous system (CNS) tumors were thought to result from genetic predisposition. However, within the last decade, new DNA sequencing methods have led to an increased recognition of high-risk cancer predisposition syndromes in children with CNS tumors. Thus, genetic predisposition is increasingly impacting clinical pediatric neuro-oncology. METHODS: In this narrative review, we discuss the current understanding of genetic predisposition to childhood CNS tumors and provide a general overview of involved research methodologies and terminology. Moreover, we consider how germline genetics may influence neurosurgical practice. RESULTS: Introduction of next-generation DNA sequencing has greatly increased our understanding of genetic predisposition to pediatric CNS tumors by enabling whole-exome/-genome sequencing of large cohorts. To date, the scientific literature has reported germline sequencing findings for more than 2000 children with CNS tumors. Although varying between tumor types, at least 10% of childhood CNS tumors can currently be explained by rare pathogenic germline variants in known cancer-related genes. Novel methodologies continue to uncover new mechanisms, suggesting that a much higher proportion of children with CNS tumors have underlying genetic causes. Understanding how genetic predisposition influences tumor biology and the clinical course in a given patient may mandate adjustments to neurosurgical treatment. CONCLUSION: Germline genetics is becoming increasingly important to clinicians, including neurosurgeons. This review provides an updated overview of genetic predisposition to childhood CNS tumors with focus on aspects relevant to pediatric neurosurgeons.
BACKGROUND: Historically, few pediatric central nervous system (CNS) tumors were thought to result from genetic predisposition. However, within the last decade, new DNA sequencing methods have led to an increased recognition of high-risk cancer predisposition syndromes in children with CNS tumors. Thus, genetic predisposition is increasingly impacting clinical pediatric neuro-oncology. METHODS: In this narrative review, we discuss the current understanding of genetic predisposition to childhood CNS tumors and provide a general overview of involved research methodologies and terminology. Moreover, we consider how germline genetics may influence neurosurgical practice. RESULTS: Introduction of next-generation DNA sequencing has greatly increased our understanding of genetic predisposition to pediatric CNS tumors by enabling whole-exome/-genome sequencing of large cohorts. To date, the scientific literature has reported germline sequencing findings for more than 2000 children with CNS tumors. Although varying between tumor types, at least 10% of childhood CNS tumors can currently be explained by rare pathogenic germline variants in known cancer-related genes. Novel methodologies continue to uncover new mechanisms, suggesting that a much higher proportion of children with CNS tumors have underlying genetic causes. Understanding how genetic predisposition influences tumor biology and the clinical course in a given patient may mandate adjustments to neurosurgical treatment. CONCLUSION: Germline genetics is becoming increasingly important to clinicians, including neurosurgeons. This review provides an updated overview of genetic predisposition to childhood CNS tumors with focus on aspects relevant to pediatric neurosurgeons.
Authors: Chenan Zhang; Quinn T Ostrom; Helen M Hansen; Julio Gonzalez-Maya; Donglei Hu; Elad Ziv; Libby Morimoto; Adam J de Smith; Ivo S Muskens; Cassie N Kline; Zalman Vaksman; Hakon Hakonarson; Sharon J Diskin; Carol Kruchko; Jill S Barnholtz-Sloan; Vijay Ramaswamy; Francis Ali-Osman; Melissa L Bondy; Michael D Taylor; Catherine Metayer; Joseph L Wiemels; Kyle M Walsh Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: H Tettelin; K E Nelson; I T Paulsen; J A Eisen; T D Read; S Peterson; J Heidelberg; R T DeBoy; D H Haft; R J Dodson; A S Durkin; M Gwinn; J F Kolonay; W C Nelson; J D Peterson; L A Umayam; O White; S L Salzberg; M R Lewis; D Radune; E Holtzapple; H Khouri; A M Wolf; T R Utterback; C L Hansen; L A McDonald; T V Feldblyum; S Angiuoli; T Dickinson; E K Hickey; I E Holt; B J Loftus; F Yang; H O Smith; J C Venter; B A Dougherty; D A Morrison; S K Hollingshead; C M Fraser Journal: Science Date: 2001-07-20 Impact factor: 47.728
Authors: Cassie N Kline; Nancy M Joseph; James P Grenert; Jessica van Ziffle; Eric Talevich; Courtney Onodera; Mariam Aboian; Soonmee Cha; David R Raleigh; Steve Braunstein; Joseph Torkildson; David Samuel; Michelle Bloomer; Alejandra G de Alba Campomanes; Anuradha Banerjee; Nicholas Butowski; Corey Raffel; Tarik Tihan; Andrew W Bollen; Joanna J Phillips; W Michael Korn; Iwei Yeh; Boris C Bastian; Nalin Gupta; Sabine Mueller; Arie Perry; Theodore Nicolaides; David A Solomon Journal: Neuro Oncol Date: 2017-05-01 Impact factor: 12.300
Authors: Anna Byrjalsen; Thomas V O Hansen; Ulrik K Stoltze; Mana M Mehrjouy; Nanna Moeller Barnkob; Lisa L Hjalgrim; René Mathiasen; Charlotte K Lautrup; Pernille A Gregersen; Henrik Hasle; Peder S Wehner; Ruta Tuckuviene; Peter Wad Sackett; Adrian O Laspiur; Maria Rossing; Rasmus L Marvig; Niels Tommerup; Tina Elisabeth Olsen; David Scheie; Ramneek Gupta; Anne-Marie Gerdes; Kjeld Schmiegelow; Karin Wadt Journal: PLoS Genet Date: 2020-12-17 Impact factor: 5.917
Authors: D Williams Parsons; Angshumoy Roy; Yaping Yang; Tao Wang; Sarah Scollon; Katie Bergstrom; Robin A Kerstein; Stephanie Gutierrez; Andrea K Petersen; Abhishek Bavle; Frank Y Lin; Dolores H López-Terrada; Federico A Monzon; M John Hicks; Karen W Eldin; Norma M Quintanilla; Adekunle M Adesina; Carrie A Mohila; William Whitehead; Andrew Jea; Sanjeev A Vasudevan; Jed G Nuchtern; Uma Ramamurthy; Amy L McGuire; Susan G Hilsenbeck; Jeffrey G Reid; Donna M Muzny; David A Wheeler; Stacey L Berg; Murali M Chintagumpala; Christine M Eng; Richard A Gibbs; Sharon E Plon Journal: JAMA Oncol Date: 2016-05-01 Impact factor: 31.777
Authors: Scott Newman; Joy Nakitandwe; Chimene A Kesserwan; Elizabeth M Azzato; David A Wheeler; David W Ellison; James R Downing; Jinghui Zhang; Kim E Nichols; Michael Rusch; Sheila Shurtleff; Dale J Hedges; Kayla V Hamilton; Scott G Foy; Michael N Edmonson; Andrew Thrasher; Armita Bahrami; Brent A Orr; Jeffery M Klco; Jiali Gu; Lynn W Harrison; Lu Wang; Michael R Clay; Annastasia Ouma; Antonina Silkov; Yanling Liu; Zhaojie Zhang; Yu Liu; Samuel W Brady; Xin Zhou; Ti-Cheng Chang; Manjusha Pande; Eric Davis; Jared Becksfort; Aman Patel; Mark R Wilkinson; Delaram Rahbarinia; Manish Kubal; Jamie L Maciaszek; Victor Pastor; Jay Knight; Alexander M Gout; Jian Wang; Zhaohui Gu; Charles G Mullighan; Rose B McGee; Emily A Quinn; Regina Nuccio; Roya Mostafavi; Elsie L Gerhardt; Leslie M Taylor; Jessica M Valdez; Stacy J Hines-Dowell; Alberto S Pappo; Giles Robinson; Liza-Marie Johnson; Ching-Hon Pui Journal: Cancer Discov Date: 2021-12-01 Impact factor: 39.397